Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 3,418 Shares of Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

uniQure Stock Performance

Shares of uniQure stock traded up $8.00 on Tuesday, reaching $15.30. 61,665,105 shares of the stock were exchanged, compared to its average volume of 1,618,237. The firm has a market capitalization of $745.72 million, a PE ratio of -1.47 and a beta of 0.89. uniQure has a 1-year low of $3.73 and a 1-year high of $17.39. The business has a fifty day moving average price of $6.20 and a two-hundred day moving average price of $6.08. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, research analysts anticipate that uniQure will post -3.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of research reports. The Goldman Sachs Group lowered their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a research note on Tuesday. Finally, Royal Bank of Canada dropped their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $27.33.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP purchased a new position in shares of uniQure in the 3rd quarter valued at about $49,000. China Universal Asset Management Co. Ltd. grew its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the period. Atria Investments Inc purchased a new position in uniQure in the third quarter valued at about $53,000. Quarry LP acquired a new stake in shares of uniQure during the 3rd quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.